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a b s t r a c t 
We describe serial MR-spectroscopy studies in a patient with systemic lupus erythematosus 
and headache. We used MR-spectroscopy to monitor disease activity during periods with 
and without headache. 
MR-spectroscopy investigates metabolic alterations and was used to explore the patho- 
physiological mechanism involved in the complications of systemic lupus erythematosus. 
Our patient underwent serial conventional MRI and MR-spectroscopy at times of con- 
trolled and uncontrolled headache, with or without visual aura. 
MR-spectroscopy showed an increase in the choline/creatine ratio in thalamus and pos- 
terior white matter only during periods of uncontrolled headache with visual aura. Conven- 
tional MRI scans were normal at all times. 
MR-spectroscopy should be used in the diagnosis and follow-up of headache in patients 
with systemic lupus erythematosus. 
© 2018 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
 
 
 
 
 
 
 
 Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune mul-
tiorgan disease which predominantly affects young women. 
Neuropsychiatric manifestations, such as psychosis and
seizures are common in SLE and may present as isolated∗ Corresponding author. 
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Headache is a common manifestation of SLE, occurring in
approximately 40% of patients and is more frequent in SLE
patients with neuropsychiatric manifestations [2] . 
To date, the specific cause of the high frequency of
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 circulating cytokines, cerebrovascular insult, or neuronal
injury could be involved [3,4] . The relationship between
headache and neuroradiological findings in these patients is
also not well known [5] . 
Conventional cerebral magnetic resonance imaging (MRI)
in SLE patients can highlight focal ischemic lesions, white
matter hyperintensity, ventricular dilation, and cortical atro-
phy [4] ; however it can also be normal [6,7] . 
Neuronal dysfunction without MRI visible brain findings
may indicate metabolic alterations. In this report we present
the case of an SLE patient with recurrent headache, in which
H-magnetic resonance spectroscopy (H-MRS) was used as a di-
agnostic and follow-up procedure. 
Case report 
A 39-year-old woman was admitted to our center for neuroim-
munology in March 2013. The anamnesis was unremarkable.
In 2005 arthritis and autoimmune thrombocytopenia were di-
agnosed. Two years later, SLE according to ARA Criteria [8] , and
Sjogren’s syndrome were diagnosed. 
The neurological history began when the patient was 13,
when she developed a catamenial migraine without aura (IHS
migraine criteria) [9] , characterized by severe pain intensity,
VAS = 10. At the age of 27 the frequency of attacks increased.
The response to therapy became less evident. Headache was
unresponsive to common analgesics; only corticosteroid ther-
apy decreased the duration and the intensity of attacks. Also
the efficacy of therapy for autoimmune diseases gradually de-
creased. In May 2013, the patient underwent psychiatric, neu-
rocognitive, and neurophysiologic evaluations. Mood and at-
tention disorder were detected; headache was severe, which
was still unresponsive to common analgesics. In September
2013, antiepileptic drugs were introduced which led to an im-
provement in the headache. Headache features changed in
April 2015, with the appearance of visual aura and right side
hypoesthesia. In June 2015, treatment with intravenous cy-
clophosphamide was started which lessened the severity of
headache. 
Over the years the patient underwent serial conventional
MRI and H-MRS at different time points during periods of un-
controlled and controlled headaches, and during headaches
with visual aura. 
Conventional MRI and H-MRS images were acquired
(Philips-Intera 1.5 T) at 3 points: at clinical presentation in May
2013, 1 year later in March 2014 after clinical remission and
2 years later in May 2015, during a period of headaches with
aura. Conventional MRI was normal in all examinations. 
Multivoxel H-MRS (TR: 1500 ms, TE: 144 ms, matrix: 16) was
acquired to evaluate normal appearing posterior periventric-
ular white matter, thalamus, and basal ganglia. The spectra
were postprocessed using the software supplied by the ma-
chine. 
The neurometabolites examined were N -acetylaspartate
(Naa: 2.0 ppm) as a neuronal marker, choline (Cho: 3.2 ppm)
as a cell membrane metabolism marker, creatine (Cr: 3.0 ppm)
as a cell energetic metabolism marker. As a control group, in June and July 2015 we studied also
6 SLE patients (6 females; age mean ± SD = 39.6 ± 2.8) with-
out aura with 2 serial MRI and H-MRS to report the Cho/Cr
value and interscan variations of metabolite concentrations.
The Cho/Cr interscan variations in the control group was cal-
culated in the left thalamus mean ± SD = 0.14 ± 0.02, left nor-
mal posterior periventricular white matter mean ± SD = 0.13
± 0.03, and left basal ganglia mean ± SD = 0.13 ± 0.02. 
The patient’s first and third H-MRS examinations showed
an increase in the Cho/Cr value in the left thalamus and left
posterior periventricular white matter compared to the sec-
ond examination ( Fig. 1 ). 
In the left thalamus, the first examination showed a
higher Cho/Cr value compared to the second examination
mean = 1.44 vs 1.22, and the third examination showed a
higher Cho/Cr value compared to the second examination
mean = 1.46 vs 1.22. In the left posterior periventricular
white matter, the first examination showed a higher Cho/Cr
value than the second examination mean = 1.40 vs 1.15, and
the third examination showed a higher Cho/Cr value than the
second examination mean = 1.43 vs 1.15. These values were
higher than the control group ( Table 1 ). 
No significant differences were found in the left basal gan-
glia. The Naa/Cr ratio value did not show any significant vari-
ation. At the present time the patient shows a remission of
symptoms. 
Discussion 
In this case report we show a correlation between the type,
severity of headache, and H-MRS abnormalities at 3 points:
at clinical presentation during severe headache, after clinical
remission, and during a period of headaches with aura. 
Some studies have demonstrated either an equal or
higher prevalence of migraine compared with tension-type
headaches in patients with SLE [10] . 
A few studies have suggested the existence of a genuine
“lupus headache” in SLE patients, which may be associated
with disease activity, is usually unresponsive to common anal-
gesics, and improves with the use of corticosteroids [11,12] .
However, this entity is still a matter of debate in the literature.
Migrainous phenomena in SLE patients have been associated
with the involvement of the central nervous system, the use
of several drugs (such as nonsteroid anti-inflammatories), and
the antiphospholipid syndrome secondary to SLE. The causes
of the headache are unclear: circulating cytokines, cerebrovas-
cular insult, or neuronal injury could be involved [13] . 
Some authors propose that there is no specific cause of
headache in SLE, and that psychosocial factors and chronic
disease may be responsible for this high prevalence [14] . How-
ever, it is still unclear whether headache in general, or only
certain types of headache, such as migraine with aura, repre-
sents part of the SLE symptom spectrum. Thalamus and pos-
terior white matter are the principal regions involved in the
headache attacks with aura [15] . 
In SLE patients with headache, conventional MRI may be
negative or may show unspecific findings such as focal lesions,
infarcts, and white matter hyperintensity. H-MRS can provide
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Fig. 1 – Multivoxel H-MRS analysis of VOI located in left thalamus (a) and left posterior periventricular white matter (b). In 
May 2013 (c-d) during a period of severe headache without aura and in May 2015 (g-h) during a period of headache with 
aura, H-MRS showed a Cho/Cr ratio higher than the second scan performed in March 2014 (e-f), during the remission of 
symptoms. 
Cho, Choline; Cr, Creatine; NAA, N -acetylaspartate. 
Table 1 – Choline/Creatine ratio of VOI in patient during severe headache (May 2013), after clinical remission (March 2014), 
during a period of headaches with aura (May 2015) and in control subjects group (mean ± SD). 
Cho/Cr May 2013 March 2014 May 2015 Control subjects 
Thalamus 1.44 1.22 1.46 1.18 ± 0.01 
Posterior white matter 1.40 1.15 1.43 1.14 ± 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 supplemental information in neuropsychiatric SLE patients in
whom structural MRI failed to show focal changes [16] . 
Systemic lupus erythematosus with Sjögren syndrome has
been recognized in the literature. In Sjögren syndrome, MRI
suggests discrete cerebral tissue damage, T2 weighted images
may show white matter hyperintensities that are larger and
smaller than 2 mm [17–19] . 
H-MRS of the human brain in vivo provides a noninva-
sive quantification of biological compounds. Normal brain
parenchyma contains large quantities of N-acetyl groups
which originate largely from Naa, a compound located exclu-
sively in neurons and neuronal processes [20] . 
Choline is a cellular marker of membrane density and in-
tegrity; malignant tumors show an increase in the Choline
peak because of increased cellularity. Increases in the Cho ra-
tio relative to NAA and Cr is observed in other conditions such
as cerebral infarctions, inflammation, and MS, and hence in
itself, is not a specific finding. Creatine is considered both a
marker of energy metabolism’, and as a stable metabolite, and
is used for calculating metabolite ratios. The increase in the
Cho/Cr ratio has also been observed in patients with SLE in
normal-appearing brain tissue. This metabolic alteration maybe an indicator of brain injury by microinfarction, cell infiltra-
tion, membrane activation, or initial degradation [16,21,22] . 
In our patient conventional MRI was normal but H-MRS
showed abnormalities. 
In our patient at the H-MRS exams performed during the
presence of headache a significant increase of in Cho/Cr peaks
was observed compared to the second examination, during
the remission symptoms, and control group. 
A decrease in Naa in SLE patients has been reported in
the literature and probably reflects neuronal loss and dysfunc-
tions [5,22] . 
The absence of an Naa change in our case is in agreement
with the reversibility of symptoms which suggest the absence
of neuronal death. 
This case therefore suggests that H-MRS might be useful in
the diagnosis and follow-up of headache in neuropsychiatric
SLE. 
In conclusion, in our patient H-MRS showed metabolic al-
terations in the thalamus and normal-appearing white matter
during migraine attacks. These alterations may be due to an
inflammatory process, and H-MRS can help in elucidating the
pathogenesis of neuropsychiatric SLE. 
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